Consensus Mesoblast Limited

Stocks

MSB

AU000000MSB8

Biotechnology & Medical Research

Delayed Australian S.E. 01:50:51 2026-10-02 EDT			5-day change	1st Jan Change
2.050 ^AUD	-0.97%		-5.09%	-24.63%

09-24	Sector Update: Healthcare Stocks Advance Late Afternoon	MT
09-24	Mesoblast Limited Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product	CI

Evolution of the Average Target: Mesoblast Limited

Evolution of the Target Price: Mesoblast Limited

Changes in Analyst Recommendations: Mesoblast Limited

0b0e399407de2b37a84bcd9dd832c03.vtkUd401CVeQktsgZKqlwi0fxOG3ilECRTVI7wSIT9A.xq0tJLRXWmf78OJ6UfLwsx9QqJiH0yNQNXEfvXbvIJLajnUZyVBGNMjG7w~13cab77dcd9e538f76de8591f7b40beb

Analysts' recommendations: Mesoblast Limited

03-09	Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys	MT
03-01	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
01-13	Mesoblast Likely to Complete More Ryoncil Therapies than Expected in Fiscal 2026, Says Jefferies	MT
11-05	Mesoblast to Meet US FDA on Opioid Cessation Data for Back Pain Drug	MT
11-04	Mesoblast Says US FDA Schedules Meeting in Early December to Discuss Data from Chronic Low Back Pain Study	MT
11-04	Mesoblast to meet with FDA next month to discuss rexlemestrocel-L and opioid cessation	RE
25-10-13	Mesoblast to Complete Ryoncil Treatment in Fiscal Year 2026 on 63 Patients, Jefferies Says	MT
25-08-05	Canaccord Genuity Starts Mesoblast at Buy with AU$2.97 Price Target	MT
24-12-23	Jefferies Downgrades Mesoblast to Hold From Buy; Price Target is AU$2.30	MT
24-09-24	Maxim Upgrades Mesoblast to Buy From Hold	MT
24-08-29	Jefferies Upgrades Mesoblast to Buy From Hold; Price Target is AU$1.10	MT
23-08-31	Cantor Fitzgerald Adjusts Price Target on Mesoblast to $17 From $23, Maintains Overweight Rating	MT
23-08-07	Maxim Downgrades Mesoblast to Hold From Buy	MT
23-08-04	Piper Sandler Downgrades Mesoblast to Neutral From Overweight, Adjusts Price Target to $2 From $7	MT
23-08-04	William Blair Downgrades Mesoblast to Market Perform From Outperform	MT
23-08-04	Chardan Trims Price Target on Mesoblast to $1.50 From $2, Maintains Sell Rating	MT
23-05-30	Chardan Cuts Price Target on Mesoblast to $2 From $2.50 Reflecting Increased Share Count Dilution, Reiterates Sell Rating	MT
23-02-01	Cantor Fitzgerald Reiterates Mesoblast at Overweight With $23 Price Target	MT
22-12-06	Jefferies Downgrades Mesoblast to Hold From Buy	MT
22-09-06	Piper Sandler Starts Mesoblast at Overweight With $7 Price Target	MT
22-06-03	Chardan Lowers Mesoblast's Price Target to $2.50 From $6.50, Maintains Sell Rating	MT
21-08-31	Mesoblast : Jefferies Downgrades Mesoblast to Hold From Buy	MT
21-08-31	Mesoblast : Chardan Adjusts Mesoblast's Price Target to $6.50 From $7.50, Maintains Sell Rating	MT
21-04-07	Mesoblast : Maxim Group Upgrades Mesoblast to Buy From Hold, Sets $18 Price Target	MT
21-01-19	Mesoblast : Jefferies & Co Downgrades Mesoblast to Hold From Buy	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MESOBLAST LIMITED					+75.68%
	WUXI APPTEC CO., LTD.					+11.79%
	ARGENX SE					+23.73%
	LONZA GROUP AG					+22.76%
	IQVIA HOLDINGS INC.					+10.75%
	REVOLUTION MEDICINES, INC.					+25.05%
	BEONE MEDICINES AG					+20.83%
	CELLTRION, INC.					+45.83%
	WUXI BIOLOGICS (CAYMAN) INC.					+3.91%
	INSMED INCORPORATED					+82.1%
	Average					+32.24%
	Weighted average by Cap.					+23.80%